CMPX ▼ -3.8% - Compass Therapeutics, Inc.
$CMPX - Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
24-OCT-2026 04:15 AM ET
Share this post
More filings for $CMPX
CMPX - Compass Therapeutics, Inc. - SEC Filing Update (10-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 10, 2026CMPX ▲ +2.7% - Compass Therapeutics, Inc.Nov 9, 2026CMPX ▲ +1.5% - Compass Therapeutics, Inc.Nov 6, 2026CMPX ▲ +1.3% - Compass Therapeutics, Inc.Nov 2, 2026CMPX ▲ +1.6% - Compass Therapeutics, Inc.Sep 23, 2026CMPX ▼ -13.2% - Compass Therapeutics, Inc.Sep 22, 2026
View full $CMPX filing history →💬 Comments
Loading comments…
Leave a comment